Overview

Response of Patients on Surveillance for Prostate Cancer to Dutasteride

Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
Hypothesis: That, in men on surveillance for favorable risk prostate cancer treated with dutasteride, prostate specific antigen (PSA) kinetics is of value in identifying those men who harbor occult high grade prostate cancer. The study will determine the prevalence of a secondary rise in PSA > 0.5 ng/ml and the PSA doubling time in subjects on surveillance being treated with dutasteride.
Details
Lead Sponsor:
Sunnybrook Health Sciences Centre
Collaborator:
Toronto Sunnybrook Regional Cancer Centre
Treatments:
Dutasteride